Preclinical testing demonstrates promising anticancer activity of a simple selenophene derivative in human lung cancer cells, suggesting therapeutic potential for selenium-based flavonoids.
Previously, we documented the synthesis and assessed the biological effects of chalcones containing selenium against HT‐29 human colorectal adenocarcinoma cells, demonstrating their significant potential. As research on selenium‐containing flavonoids remains limited, this article outlines our design and synthesis of three selenium‐based flavonols and three 2‐styrylchromones. We conducted evaluations of these compounds to determine their impact on human lung cancer cells (A549, H1975, CL1‐0, and CL1‐5) and their influence on normal lung fibroblast MRC5 cells. Additionally, we included selenium‐based chalcones in our testing for comparative purposes. Our findings highlight that the simplest compound, designated as compound 1 , exhibited the most promising performance among the tested molecules.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: